Isis antisense drug lowers triglycerides; Phase III ongoing
This article was originally published in Scrip
Isis Pharmaceuticals has one Phase III clinical trial under way with a second late-stage trial expected to start before the end of 2015 for its antisense drug volanesorsen (ISIS-APOCIIIRx), which was able to significantly lower patients' triglyceride levels in a Phase II study.
You may also be interested in...
Phase III data showing statistically significant reduction of triglycerides will bolster the pivotal data expected early next year. Akcea is not concerned by the study’s 20% dropout rate because there were no discontinuations in a subset of patients with FCS.
Wave Life Sciences Ltd. entered into a collaboration agreement with Pfizer Inc. for the discovery and development of nucleic acid therapeutics addressing five metabolic disease targets, adding $40m in upfront cash to its balance sheet that will help the newly public biotechnology firm keep its in-house focus on rare, genetic neurological and neuromuscular diseases.
When the US FDA approved Olumiant (baricitinib) for RA, it insisted on a lower dose because of fears of blood clots. Now that an NIH trial has shown that the product plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized COVID patients, Olumaint may get an emergency use authorization from FDA to treat a condition that itself causes blood clots. That doesn't mean the black box is going away; it's just a reminder that there is as much magic and mystery to medicine sometimes as there is science.